Abstract Purpose: The interleukin-13 receptor a2 (IL-13Ra2) is a glioma-restricted cell-surface epitope not otherwise detected within the central nervous system. Here, we report a novel approach for targeting malignant glioma with IL-13Ra2^specific CTLs. Experimental Design: Artificial antigen-presenting cells (aAPC) were made by coating human leukocyte antigen (HLA)-A2/pIL-13Ra2 345-354 tetrameric complexes, anti-CD28 antibody, and CD83 molecules to cell-sized latex beads, and used to stimulate IL-13Ra2^specific CTLs from the peripheral blood mononuclear cells of HLA-A2 + healthy donors. After multiple stimulations, the induced CTLs were analyzed for tetramer staining, IFN-g production, and CTL reactivity. Results: Tetramer staining assay showed that the induced CTLs specifically bound HLA-A2/ pIL-13Ra2 345-354 tetramers. The CTLs specifically produced IFN-g in response to the HLA-A2/pIL-13Ra2 345-354 -aAPCs and exhibited specific lysis against T2 cells pulsed with the peptide pIL-13Ra2 [345][346][347][348][349][350][351][352][353][354] and HLA-A2 + glioma cells expressing IL-13Ra2 [345][346][347][348][349][350][351][352][353][354] , whereas HLA-A2 -glioma cell lines that express IL-13Ra2 [345][346][347][348][349][350][351][352][353][354] could not be recognized by the CTLs. The peptide-specific activity was inhibited by anti^HLA class I monoclonal antibody. Conclusion: The induced CTLs specific for IL-13Ra2 345-354 peptide could be a potential target of specific immunotherapy for HLA-A2 + patients with malignant glioma.
Despite significant advances in modern microsurgery, radiotherapy, and chemotherapy, the prognosis for patients with malignant glioma remains poor (1) . Therefore, the development of a new treatment modality is needed. Although the central nervous system (CNS), and tumors that arise therein, reside in an ''immunologically privileged'' site (2), many data have successfully shown that effective anti-CNS tumor immune responses can be induced in preclinical models using syngeneic tumor-and dendritic cell -based vaccines (3 -5). In addition, activated, antitumor immune cells have the potential to migrate into the CNS and to selectively destroy malignant cells that have infiltrated normal CNS tissues (6) . Therefore, immunotherapy for glioma is an attractive alternative treatment option.
The induction of antigen-specific CTLs has been suggested to be highly efficacious in the prevention and treatment of various types of tumors (7) . CTLs recognize ''processed'' peptides that are derived from endogenous proteins and presented on the cell surface in association with MHC class I molecules (7, 8) . Peptides that bind to a given MHC class I molecule have been shown to share common amino acid motifs, which are called major anchor motifs (8) . Hence, tumor-specific CTLs can recognize and select the antigenic peptides by scanning peptide sequences, and then kill tumor cells in an antigenic peptide-specific fashion. Interleukin-13 receptor a2 (IL-13Ra2) chain has been reported to be abundantly and specifically overexpressed in malignant glioma and not otherwise presented in the normal brain (9 -11) . IL-13Ra2 -specific CTLs can be generated in vitro using peptide-pulsed autologous dendritic cells as antigenpresenting cells (APC; ref. 12). However, this method is timeconsuming and expensive due to the limited availability of donor-derived dendritic cells. To date, several reports indicated effective stimulation of T cells by human leukocyte antigen (HLA)-peptide ligand coating on aAPCs, such as liposomes (13, 14) and microbeads (15 -18) . The aAPCs simulate the natural APCs (such as dendritic cells, macrophages, and B cells), which are able to provide the dual signals (the antigen-specific and costimulatory signals) for Tcell activation. These aAPCs can be prepared by coating the T-cell receptor ligand (peptide-MHC) and costimulatory molecules (such as B7) on a cell-sized bead, and it provides a practical and convenient approach to generating antigenspecific T cells for adoptive immunotherapy.
In this study, we explored a simple and efficient method to induce IL-13Ra2 345-354 -specific CTLs from the peripheral blood mononuclear cells (PBMC) of HLA-A2 + normal donors using aAPCs made by coating HLA-A2/pIL-13Ra2 [345] [346] [347] [348] [349] [350] [351] [352] [353] [354] complexes, anti-CD28 antibody, and CD83 to cell-sized latex microbeads in vitro, in which these CTLs kept their antigenspecific cytolytic properties.
Materials and Methods
Cell line and cell culture. T2 cells were kindly provided by Prof. Nicholas Zavazava (Kiel University, Kiel, Germany). This cell bears the HLA-A*0201 gene, but expresses a very low level of cell-surface HLA-A2.1 molecules and is unable to present endogenous antigens due to a deletion of most of the MHC class II region, including the transporter associated with antigen processing and genes encoding for immunoproteasomal subunits. This cell line was maintained in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (HyClone) and antibiotics. Glioma cell lines U251 (HLA-A2 + , IL13Ra2 + ) and A172 (HLA-A2 -, IL-13Ra2 + ) were purchased from the American Type Culture Collection. These glioma cell lines were cultured in DMEM supplemented with 10% fetal bovine serum and antibiotics.
Synthetic peptides. The following HLA-A2 -restricted peptides were used in this study: the IL-13Ra2 -derived peptide WLPFGFILI (referred to as pIL-13Ra2 345-354 ; 12) and the control peptide HIV-Gag peptide SLYNTVATL (pHIV; ref. 19 ). Peptides were synthesized by standard solid-phase chemistry and characterized by mass spectrometry. The purity of the synthetic peptides was >95% as indicated by analytical HPLC. Lyophilized peptides were dissolved in DMSO and stored at -80jC after dilution in PBS.
HLA class I typing. HLA class I typing was done with microcytotoxicity by Lambda Antigen Traye Class I (One Lamda, Inc.).
Detection of IL-13Ra2 gene expression in glioma cell lines by reverse transcription-PCR. The expression of IL-13Ra2 mRNA in glioma cell lines U251 and A172 was detected with reverse transcription-PCR. The primers used for amplification of human IL-13Ra2 and GAPDH were as follows: IL-13Ra2, 5 ¶-TGGTCAGAAGTGTGCCTGTC-3 ¶ (S) and 5 ¶-TCTGCCCAGGAACTTTGAAC-3 ¶ (AS); GAPDH, 5 ¶-ACAGTCAGCCG-CATCTTCTT-3 ¶ (S) and 5 ¶-TTGATTTTGGAGGGATCTCG-3 ¶ (AS). The PCR reactions using Ex Taq DNA polymerase (Life Technologies) were subjected to 30 amplification cycles; conditions consisted of 94jC denaturation for 30 s, 57jC primer annealing for 30 s, followed by primer extension at 72jC for 1 min.
Preparation of HLA-A2/pIL-13Ra2 345-354 tetramers. Synthesis of HLA-A2/pIL-13Ra2 345-354 tetramers was carried out according to the protocol of Altman et al. (20) . Briefly, plasmids encoding HLA-A*0201 (heavy chain) molecules with a COOH-terminal biotinylation site and human h2m molecule were constructed by insertion of the target genes into pET28a. The heavy chain and h2m molecules were expressed in Escherichia coli, purified from inclusion bodies, and then refolded in the presence of excess pIL-13Ra2 [345] [346] [347] [348] [349] [350] [351] [352] [353] [354] to form the HLA-A2/ pIL-13Ra2 345-354 monomeric product. The folded product was then subjected to enzymatic biotinylation by BirA enzyme (Avidity) at 25jC for 12 h. This biotinylated HLA-A2/pIL-13Ra2 345-354 monomer was used for the preparation of the HLA-A2/pIL-13Ra2 345-354 tetramer. The HLA-A2/pIL-13Ra2 345-354 tetramer was produced by mixing the purified biotinylated monomer with FITC-labeled streptavidin (Sigma) at a molar ratio of 4:1. HLA-A2/pHIV tetramer was also prepared according to the manufacturer's protocol.
Generation of HLA-A2/pIL-13Ra2 345-354 -aAPCs. The 5-Am sulfate polystyrene latex (interfacial Dynamics) was incubated sequentially with streptavidin (1 Ag/10 7 beads; Sigma), CD28-specific antibody, and CD83 (1 Ag and 1.5 Ag/10 7 beads, respectively; BD PharMingen) for 30 min in 1-mL PBS per 10 7 beads at 4jC on a rotator. The beads were then incubated with biotinylated HLA-A2/pIL-13Ra2 345-354 complexes (2 Ag/10 7 beads) for 1 h at 4jC on a rotator. After each incubation step, the beads were washed with PBS. The HLA-A2/pIL-13Ra2 345-354 -aAPCs were stored in PBS at 4jC.
Induction of CTL. PBMCs from five healthy HLA-A2
+ donors were separated using standard Ficoll-Hypaque (Sigma) gradient density centrifugation. The PBMCs were stimulated with HLA-A2/pIL13Ra2 345-354 -aAPCs in vitro using the protocol adapted from previous studies (21) . Briefly, The PBMCs were used as responder cells and stimulated with HLA-A2/pIL-13Ra2 345-354 -aAPCs. Responder cells (3 Â 10 6 per well) were cocultured with HLA-A2/pIL-13Ra2 345-354 -aAPCs (3 Â 10 5 per well) in 24-well plates in RPMI 1640 supplemented with 10% fetal bovine serum (1 ml/well). Interleukin-7 (IL-7; 10 ng/mL; PeproTech EC) was added on day 1. IL-2 (50 units/mL, R&D Systems) was added on day 4. Medium, IL-2, and IL-7 were replenished twice a week. On day 7 and weekly thereafter, responder cells were collected, counted, and replated at 3 Â 10 6 per well, together with 3 Â 10 5 HLA-A2/pIL-13Ra2 345-354 -aAPCs per well in RPMI 1640 with 10% fetal bovine serum, 10 ng/mL IL-7, and 50 units/mL IL-2. After a total of four rounds of stimulations in vitro, responder cells were tested for tetramer staining and cytotoxicity assay.
Tetramer staining. Tetramer staining was done as previously described (22, 23) . In brief, 1 Â 10 6 cells were incubated in 100-AL fluorescence-activated cell sorting staining buffer (PBS supplemented with 1% bovine serum albumin and 0.05% NaN 3 ) with 20 Ag/mL HLA-A2/peptide tetramer at 37jC for 30 min. Cells were washed with PBS and subsequently incubated with phycoerythrin-Cy5 -labeled anti-CD8 antibody (BD PharMingen) at 4jC for 30 min. All cells were washed with PBS twice after being stained, and then fixed in 1% formaldehyde. Stained cells were analyzed with FACSCalibur (Becton Dickinson).
ELISA. To determine the frequency of T cells capable of responding to a specific stimulus by secretion of IFN-g, an enzymelinked immunospot (ELISPOT) assay was done. The HLA-A2/pIL- ; ref. 24 ) and a control isotypic mAb of irrelevant specificity IgG2 (BD PharMingen) at a final concentration of 30 Ag/mL for 40 min at 4jC before cytotoxicity assay. After incubation, the target cells were mixed with effector cells for the 51 Cr release assay. Statistical analysis. All data in this study were analyzed using SPSS version 11.0 software (SPSS). P < 0.05 was considered as statistically significant. (Table 1) .
ELISPOT assay. The ELISPOT assay was used to determine the frequency of individual antigen-specific IFN-g producing T cells. As shown in at an effector/target ratio of 50:1. However, the CTLs showed an f10% cytolysis against T2pHIV, A172 (HLA-A2 -, IL-13Ra2 + ), K562, and the T2 without a pulsed peptide at the same effector/target ratio (Fig. 3A) . The specific killing activity of the CTLs induced by the HLA-A2/pIL-13Ra2 345-354 -aAPCs against specific target cells was much more obvious than in any other control group (P < 0.05). The specific CTLs for pIL-13Ra2 [345] [346] [347] [348] [349] [350] [351] [352] [353] [354] induced by HLA-A2/pIL-13Ra2 345-354 -aAPCs from the other four normal donors showed similar specific lysis (Table 1 ). This result shows that the cytotoxicity of the HLA-A2/pIL13Ra2 345-354 -aAPCs -induced CTL is pIL-13Ra2 345-354 specific. Fig. 3B and C, incubation of T2pIL-13Ra2 [345] [346] [347] [348] [349] [350] [351] [352] [353] [354] and U251 target cells with W6/32 led to the inhibition of the targeted cells lysis, whereas mouse IgG2, used as an isotype control, showed no effect. These results suggested that the HLA-A2/pIL-13Ra2 345-354 -aAPCs -induced CTLs lysed the specific targets in a HLA class I -restricted manner.
Discussion
Malignant gliomas represent a significant class of CNS tumors derived from the glial lineage. Despite recent advances in traditional treatment options, the prognosis for these patients has not changed appreciably. The 5-year survival rate for patients harboring the most common class of gliomas, glioblastoma multiforme, is <2% (25) . In an effort to improve the outcome of patients with respectable brain tumors, there have been attempts to give adjunctive therapies consisting of radiation with or without chemotherapy. Thus far, research over three decades has failed to provide definitive evidence of improved outcome (i.e., overall survival and disease-free survival) in patients. Clearly, modalities other than radiation and/or chemotherapy must be explored in an adjuvant setting. Immune-based treatments represent a promising new class of therapy designed to harness the immune system to specifically eradicate malignant cells. However, immunotherapy for tumors located in the CNS has generally not achieved the results seen for peripherally located tumors (26 -29) . These previous findings have historically been ascribed to the ''immune privilege'' of the CNS (30) . In reality, however, the immune privilege of the brain is not absolute but was originally used to describe the observation that Research.
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Tumor-specific CD8-positive CTLs constitute the most important effector cells for antitumor responses (8) . It has previously been shown that in vitro specific CTLs can be generated using peptide-pulsed autologous dendritic cells as APCs (42, 43) . However, CTL expansion to clinically relevant amounts requires multiple leukophoreses to obtain enough autologous dendritic cells. Variability in both quantity and quality of obtained dendritic cells, which presumably relate to underlying diseases and the pretreatment of the patients, also significantly affects the viability of dendritic cell -based therapeutics. For these reasons, use of dendritic cells has been a limiting step in ex vivo expansion of T cells (18) . Strategy of aAPC offers a promising way to overcome the disadvantages of natural APCs. CTLs generated by artificial stimulation protocols can kill both peptide-loaded and natural target cells (18, 44, 45) . The presented data showed that CTLs specific for pIL13Ra2 345-354 could be induced in vitro with the aAPCs coating HLA-A2/pIL-13Ra2 345-354 , anti-CD28 antibody, and CD83 molecule to cell-sized latex beads. The HLA-A2 + PBMCs were induced to generate pIL-13Ra2 345-354 -specific CTLs in vitro by coculture with the HLA-A2/pIL-13Ra2 345-354 -aAPCs, and specificity of the aAPC-induced CTLs was confirmed by both their binding to HLA-A2/pIL-13Ra2 345-354 tetramers and killing activity against HLA-A2/pIL-13Ra2 345-354 -bearing cells. Following this procedure, we found that the induced CTLs, derived from PBMCs in a HLA-A2 + healthy donor, could kill the HLA-A2 + pIL-13Ra2 345-354 + glioma cell lines when stimulated with HLA-A2/pIL-13Ra2 345-354 -aAPCs in vitro. The specific killing activity of CTL induced by the HLA-A2/ pIL-13Ra2 345-354 -aAPCs against specific target cells T2pIL-13Ra2 345-354 and U251 was much more effective than that of any other control group. The results indicated that the cytotoxicity of the aAPCs-induced CTL is antigen specific (i.e., against the target cells bearing the corresponding HLA-A2/pIL13Ra2 345-354 complexes). In addition, it is possible to increase the percentage of antigen-specific CTL by sorting the cells after staining with tetramer and isolating the positive cells with magnetic beads loaded with anti-FITC antibody (Miltenyi System). Many groups have applied this approach to obtain higher percentages of antigen-specific CTLs that could be further expanded with aAPC or beads coated with anti-CD3/ CD28 mAb (46) . Therefore, this technique can be extrapolated to expand enough T cells for clinical use.
For clinical studies, HLA tetramer -based aAPCs have several distinct advantages over cellular APCs including dendritic cells. One of these is ease of preparation, which is not required for sterile cell culture and cytokines, thereby reducing both the variability and expense associated with ex vivo expansion. The variability is particularly important when considering therapies for cancer because there have been reported defects in dendritic cells obtained from patients with malignancies (47) . Another advantage is the good stability of aAPCs, unlike the biological variability and patient-to-patient variation when producing cellular APCs such as dendritic cells. In addition, aAPCs can present defined combinations of MHC alleles and peptides and be easily adapted using other MHC alleles and/or peptides, so that immunodominant or subdominant epitopes can be expanded preferentially. When cellular APCs are used, an array of MHC molecules is used and a broad but uncontrolled MHC restricted response is generated. The last advantage is the ability to control the combination of costimulatory complexes associated with aAPCs, unlike cellular APCs that may participate in the T cell-APC interaction in such a way that it promotes tolerance or anergy. For example, on T-cell activation, B7 binding to CTLA-4 instead of CD28 would limit T-cell expansion (48) . It is convenient to prepare aAPCs coated with anti-CD28, which binds specifically to CD28, avoiding the binding of B7 to CTLA-4. In this study, we used a combination of anti-CD28 and CD83 for the generation of a costimulatory signal because CD83 molecule is important in (a) priming naive CD8 + T cells; (b) driving their antigen-specific expansion; and (c) supporting their long-term survival and function when coupled to aAPCs (49) . In contrast to other types of aAPCs previously engineered by others (50), there is no need for additional molecules like intercellular adhesion molecule-1 or lymphocyte function-associated antigen-3. The antigen-specific CTL can be successfully induced with the HLA-A2/pIL-13Ra2 345-354 -aAPCs in vitro. Further studies need to compare the efficiency of this approach with those of other techniques such as aAPCs with a combination of other costimulatory molecules.
The use of aAPC represents the state-of-the-art generation of antigen-specific CTLs for adoptive immunotherapy. Thus, HLA tetramer -based aAPCs coated with a HLA/peptide complex, anti-CD28 antibody, and CD83 molecule could provide a useful tool for the reproducible expansion of specific CTLs in vitro and significantly advance the field of adoptive immunotherapy. HLA-A2/pIL-13Ra2 345-354 -aAPCs could be used as a standardized, ''off-the-shelf'' reagent to enrich pIL-13Ra2 345-354 -specific CTLs for the treatment of patients with malignant gliomas.
